238 related articles for article (PubMed ID: 12850128)
1. Salmeterol & fluticasone 50 microg/250 microg bid in combination provides a better long-term control than salmeterol 50 microg bid alone and placebo in COPD patients already treated with theophylline.
Dal Negro RW; Pomari C; Tognella S; Micheletto C
Pulm Pharmacol Ther; 2003; 16(4):241-6. PubMed ID: 12850128
[TBL] [Abstract][Full Text] [Related]
2. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD.
Hanania NA; Darken P; Horstman D; Reisner C; Lee B; Davis S; Shah T
Chest; 2003 Sep; 124(3):834-43. PubMed ID: 12970006
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study.
Nathan RA; Rooklin A; Schoaf L; Scott C; Ellsworth A; House K; Dorinsky P
Clin Ther; 2006 Jan; 28(1):73-85. PubMed ID: 16490581
[TBL] [Abstract][Full Text] [Related]
4. A short-term comparison of fluticasone propionate/salmeterol with ipratropium bromide/albuterol for the treatment of COPD.
Donohue JF; Kalberg C; Emmett A; Merchant K; Knobil K
Treat Respir Med; 2004; 3(3):173-81. PubMed ID: 15219176
[TBL] [Abstract][Full Text] [Related]
5. The therapeutic effects of inhaled long-acting beta2-adrenergics (LABA) and corticosteroids (ICS) are not affected by their inhalation sequence in moderate/persistent asthma.
Dal Negro RW; Micheletto C; Tognella S; Trevisan F; Guerriero M
Eur Ann Allergy Clin Immunol; 2006 May; 38(5):153-7. PubMed ID: 17058847
[TBL] [Abstract][Full Text] [Related]
6. Salmeterol/fluticasone propionate via Diskus once daily versus fluticasone propionate twice daily in patients with mild asthma not previously receiving maintenance corticosteroids.
Chuchalin A; Jacques L; Frith L
Clin Drug Investig; 2008; 28(3):169-81. PubMed ID: 18266402
[TBL] [Abstract][Full Text] [Related]
7. Salmeterol and fluticasone propionate (50/250 microg) administered via combination Diskus inhaler: as effective as when given via separate Diskus inhalers.
Chapman KR; Ringdal N; Backer V; Palmqvist M; Saarelainen S; Briggs M
Can Respir J; 1999; 6(1):45-51. PubMed ID: 10202220
[TBL] [Abstract][Full Text] [Related]
8. Salmeterol/fluticasone propionate in a Single Inhaler Device versus theophylline+fluticasone propionate in patients with COPD.
Cazzola M; Noschese P; Centanni S; Santus P; Di Marco F; Spicuzza L; Di Maria GU
Pulm Pharmacol Ther; 2004; 17(3):141-5. PubMed ID: 15123223
[TBL] [Abstract][Full Text] [Related]
9. The CONCEPT trial: a 1-year, multicenter, randomized,double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma.
FitzGerald JM; Boulet LP; Follows RM
Clin Ther; 2005 Apr; 27(4):393-406. PubMed ID: 15922813
[TBL] [Abstract][Full Text] [Related]
10. Additive effects of salmeterol and fluticasone or theophylline in COPD.
Cazzola M; Di Lorenzo G; Di Perna F; Calderaro F; Testi R; Centanni S
Chest; 2000 Dec; 118(6):1576-81. PubMed ID: 11115442
[TBL] [Abstract][Full Text] [Related]
11. Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial.
Kavuru M; Melamed J; Gross G; Laforce C; House K; Prillaman B; Baitinger L; Woodring A; Shah T
J Allergy Clin Immunol; 2000 Jun; 105(6 Pt 1):1108-16. PubMed ID: 10856143
[TBL] [Abstract][Full Text] [Related]
12. Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD.
Partridge MR; Schuermann W; Beckman O; Persson T; Polanowski T
Ther Adv Respir Dis; 2009 Aug; 3(4):1-11. PubMed ID: 19734176
[TBL] [Abstract][Full Text] [Related]
13. Effects of fluticasone plus salmeterol versus twice the dose of fluticasone in asthmatic patients.
Currie GP; Bates CE; Lee DK; Jackson CM; Lipworth BJ
Eur J Clin Pharmacol; 2003 May; 59(1):11-5. PubMed ID: 12743669
[TBL] [Abstract][Full Text] [Related]
14. Fluticasone alone or in combination with salmeterol vs triamcinolone in asthma.
Baraniuk J; Murray JJ; Nathan RA; Berger WE; Johnson M; Edwards LD; Srebro S; Rickard KA
Chest; 1999 Sep; 116(3):625-32. PubMed ID: 10492263
[TBL] [Abstract][Full Text] [Related]
15. Addition of salmeterol to fluticasone propionate treatment in moderate-to-severe asthma.
Ind PW; Dal Negro R; Colman NC; Fletcher CP; Browning D; James MH
Respir Med; 2003 May; 97(5):555-62. PubMed ID: 12735675
[TBL] [Abstract][Full Text] [Related]
16. A comparison between inhaled salmeterol and theophylline in the short-term treatment of stable chronic obstructive pulmonary disease.
Broseghini C; Testi R; Polese G; Tosatto R; Rossi A
Pulm Pharmacol Ther; 2005; 18(2):103-8. PubMed ID: 15649852
[TBL] [Abstract][Full Text] [Related]
17. The efficacy and safety of combination salmeterol (50 microg)/fluticasone propionate (500 microg) inhalation twice daily via accuhaler in Chinese patients with COPD.
Zheng JP; Yang L; Wu YM; Chen P; Wen ZG; Huang WJ; Shi Y; Wang CZ; Huang SG; Sun TY; Wang GF; Xiong SD; Zhong NS
Chest; 2007 Dec; 132(6):1756-63. PubMed ID: 17951625
[TBL] [Abstract][Full Text] [Related]
18. Comparable spirometric efficacy of tiotropium compared with salmeterol plus fluticasone in patients with COPD: a pilot study.
Bateman ED; van Dyk M; Sagriotis A
Pulm Pharmacol Ther; 2008; 21(1):20-5. PubMed ID: 17118684
[TBL] [Abstract][Full Text] [Related]
19. Combined salmeterol/fluticasone propionate versus fluticasone propionate alone in mild asthma : a placebo-controlled comparison.
Boonsawat W; Goryachkina L; Jacques L; Frith L
Clin Drug Investig; 2008; 28(2):101-11. PubMed ID: 18211118
[TBL] [Abstract][Full Text] [Related]
20. Tolerability of a salmeterol xinafoate/fluticasone propionate hydrofluoroalkane metered-dose inhaler in adolescent and adult patients with persistent asthma: a 52-week, open-label, stratified, parallel-group, multicenter study.
Cowie RL; Boulet LP; Keith PK; Scott-Wilson CA; House KW; Dorinsky PM
Clin Ther; 2007 Jul; 29(7):1390-402. PubMed ID: 17825690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
